MSology Library – Drug safety issues

Drug safety issues

PML (progressive multifocal leukoencephalopathy). This is the most recent published estimate of the risk of PML in people treated with Tysabri.

Risk of natalizumab-associated progressive multifocal leukoencephalopathy. Bloomgren and colleagues. N Engl J Med 2012;366:1870-1880.

Multiple sclerosis, natalizumab, and PML: helping patients decide. Rudick RA. Cleve Clin J Med 2011;78 Suppl 2:S18-23. Some issues to consider when deciding whether or not to start Tysabri. From the lead author of the SENTINEL study of Tysabri.

NEW A review of the JC virus that causes PML. Diotti and colleagues. Clin Dev Immunol 2013;2013:967581.


Pregnancy and MS therapies (fingolimod)

Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Lu and colleagues. Neurology 2012;79:1130-1135. A review of 15 studies looking at outcomes in people exposed to an interferon, Copaxone or Tysabri during their pregnancy.

Pregnancy and fetal outcomes after glatiramer acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. Giannini and colleagues. BMC Neurol 2012;12:124. The effect of Copaxone on pregnancies.

To return to the MSology Library, please click here

Share this article
pin it!

Related Posts